Biolinq’s “barely there” higher arm wearable affords real-time glucose insights with a color-changing interface to empower these with Kind 2 diabetes who aren’t on insulin
Biolinq, the well being tech firm behind an intradermal glucose sensor, has raised $100 million in a Collection C spherical to assist the U.S. regulatory approval course of because it strikes nearer to launching its metabolic biosensor wearable for these with Kind 2 diabetes who should not utilizing insulin.
The funding follows Biolinq’s $58 million increase final April that supported the San Diego well being tech firm’s medical trial.
Alpha Wave Ventures led the spherical, with participation from current buyers RiverVest Enterprise Companions, AXA IM Alts, LifeSci Enterprise Companions, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Options Capital.
“Our crew has spent the final decade growing a biosensor platform designed to encourage more healthy residing by offering context round an individual’s metabolic well being,” CEO Wealthy Yang stated.
The “barely there” wearable glucose sensor makes use of tiny electrochemical sensors to measure glucose ranges simply beneath the pores and skin’s floor and is worn on the higher forearm. Most notably, it features a color-changing light that gives users real-time feedback on their glucose readings, versus having to examine a secondary system.
“Biolinq has assembled world-class consultants in biosensor expertise, client electronics and semiconductor manufacturing to redefine the biowearables class,” Alpha Wave World chairman Rick Gerson stated. “With a extremely differentiated product, Biolinq is well-positioned to increase the biosensor market.”
